Cancer

The recall covers all batches of Urografin 60% manufactured between October 2020 and March 2025.

The drug targets a specific immune deficit associated with bladder cancer, offering a mechanism distinct from conventional treatments.

The alert followed official communication from Roche Nigeria after the pharmaceutical company received multiple complaints from healthcare professionals nationwide.

The acquisition involves Novartis purchasing Pikavation Therapeutics, a wholly owned subsidiary of Synnovation Therapeutics that holds the rights to SNV4818 and related research programs.

The complaints originated from Lagos University Teaching Hospital (LUTH-NSIA), where patients brought in suspected counterfeit products for administration.

Imperative Care reports that medical professionals have used its products commercially in more than 78,000 procedures, demonstrating significant market adoption and clinical trust.

Each year, approximately 20,000 Ugandan patients travel to India seeking specialized cancer care unavailable at home.

This initiative aligns with the Universal Health Coverage (UHC) agenda and seeks to transform regional facilities into dependable referral hubs that bring advanced cancer care closer to communities across the country.

The trial will enroll up to 105 Japanese men across 11 sites throughout the country, with the collected data intended to support a future marketing authorization submission for TLX591-Px in Japan.

Anktiva operates through a novel mechanism by binding to the interleukin-15 (IL-15) receptor, which triggers the proliferation and activation of natural killer cells, CD4+ cells, CD8+ cells, and memory T cells.